



9th May, 2024

<p>To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 540701 (Equity) : 974556 (Debt)</p>	<p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DCAL (ii) Series – EQ</p>
--	--

SUB.: DISCLOSURE PURSUANT TO REGULATIONS 30 and 51 OF SEBI (LODR) REGULATIONS, 2015: COMPANY’S BAVLA UNIT RECEIVED ESTABLISHMENT INSPECTION REPORT (EIR) FROM THE UNITED STATES FOOD AND DRUG ADMINISTRATION (US FDA)

Dear Sir,

With reference to the captioned subject, we would like to inform that the Company’s Bavla facility was successfully inspected by the US FDA from 4th March, 2024 to 7th March, 2024, which was intimated to the stock exchange on 8th March, 2024.

In this regard, we are pleased to share that yesterday the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection

Thus, the Company’s facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the US FDA.

Kindly take this on your record.

Thanking You,

Yours faithfully,

For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary